"Top 5 Stories of the Week: First Mining Gold (TSX:FF), Algernon Pharmaceuticals (CSE:AGN), G Mining Ventures (TSXV:GMIN), Nextech AR Solutions (CSE:NTAR), Datametrex (TSXV:DM)
While global markets are in a downtrend year to date, return drivers for active investors still abound.
"Algernon (CSE:AGN) receives requests for ongoing supply of Ifenprodil from study participants
Patients participating in Algernon Pharmaceuticals’ (AGN) clinical study in Australia and New Zealand have requested Ifenprodil for their personal use.
"Algernon Pharmaceuticals (CSE:AGN) begins manufacturing of Repirinast and launches chronic kidney disease research program
Algernon Pharmaceuticals (AGN) has awarded a contract to begin the manufacturing of a cGMP supply of its repurposed drug candidate NP-251 (Repirinast).
"Algernon Pharmaceuticals (CSE:AGN) completes enrollment in its Phase 2 study of Ifenprodil
Algernon Pharmaceuticals (AGN) has completed enrollment in its Phase 2 NP-120 (Ifenprodil) idiopathic pulmonary fibrosis (IPF) and chronic cough study.
Christopher Moreau, CEO of Algernon Pharmaceuticals sat down with Brieanna McCutcheon to discuss Algernon’s approach to the psychedelics and health care sectors.
"Algernon Pharmaceuticals (CSE:AGN) discloses novel salt patent strategy
Algernon Pharmaceuticals (AGN) has included novel salt forms of DMT in its intellectual property patent applications for AP-188 (“N,N-dimethyltryptamine” or “DMT”).
"Algernon Pharmaceuticals (CSE:AGN) receives positive feedback from the U.S. FDA for its Phase 2b Ifenprodil chronic cough study
Algernon Pharmaceuticals (AGN) has received positive feedback from the U.S. FDA for its investigation of NP-120 (Ifenprodil) for the treatment of chronic cough.
